ReviewEndocrine connections2020
TSH suppressive therapy and bone.
Review in Endocrine connections, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Association between serum TSH concentration and bone mineral density: an umbrella review.Hormones (Athens, Greece) · 2024Pooled it
- Pathophysiology, diagnosis and management of secondary osteoporosis.Nature reviews. Endocrinology · 2026Review
- TSH suppression attenuates the early efficacy of zoledronic acid in osteoporosis.Archives of osteoporosis · 2026Article
- A Comparative Evaluation of Three Time-to-Event Models Predicting 5-Year Osteoporosis Risk in Thyroid Cancer Survivors: A Nationwide Cohort Study.Endocrinology and metabolism (Seoul, Korea) · 2026Article
- Increased risk of osteoporosis among thyroid cancer survivors: the influence of postoperative levothyroxine therapy in a nationwide cohort study.Annals of surgical treatment and research · 2026Article
- Case report: A Newly Identified G-protein Subunit α-11 Loss-of-Function Variant Causing Familial Hypocalciuric Hypercalcemia Type 2 in an Italian Kindred.Frontiers in endocrinology · 2026Article
- Longitudinal Bone Density During TSH Suppression in Differentiated Thyroid Cancer: A Paired PET/CT Analysis.Cancers · 2025Article
- Effect of Thyroid-Stimulating Hormone Suppression on Bone Mineral Density in Patients with Differentiated Thyroid Carcinoma: A Single Center Retrospective Study.Journal of bone metabolism · 2025Article
- Thyroid Cancer and Physical Activity: A Bibliometric Analysis.Journal of multidisciplinary healthcare · 2025Review
- Knowledge, attitudes, and practices regarding the postoperative management and TSH suppression therapy among patients with thyroid cancer.Frontiers in oncology · 2025Article
- Levothyroxine therapy in thyroidectomized patients: ongoing challenges and controversies.Frontiers in endocrinology · 2025Review
- Bone Metabolism and Dental Implant Insertion as a Correlation Affecting on Marginal Bone Remodeling: Texture Analysis and the New Corticalization Index, Predictor of Marginal Bone Loss-3 Months of Follow-Up.Journal of clinical medicine · 2024Article
- Correlation Between Anxiety and Serum Thyroid Hormone Levels in Patients With Papillary Thyroid Carcinoma Undergoing Microwave Ablation.Depression and anxiety · 2024Article
- Trabecular Bone Score (TBS) in Individuals with Type 2 Diabetes Mellitus: An Updated Review.Journal of clinical medicine · 2023Review
- [Hypothyroidism and aging: the search for protective factors].Problemy endokrinologii · 2023Review
- Thyroid Dysfunction in Periand Postmenopausal Women-Cumulative Risks.Deutsches Arzteblatt international · 2023Review
- Bridging the Gap: Pregnancy-And Lactation-Associated Osteoporosis.Diagnostics (Basel, Switzerland) · 2023Review
- Physical activity and reduced risk of fracture in thyroid cancer patients after thyroidectomy - a nationwide cohort study.Frontiers in endocrinology · 2023Article
- Effect of Suppressive Levothyroxine Therapy on Bone Mineral Density in Young Patients with Differentiated Thyroid Carcinoma.Metabolites · 2022Article
- Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge.The Journal of clinical endocrinology and metabolism · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid hormones stimulate bone turnover in adults by increasing osteoclastic bone resorption. TSH suppressive therapy is usually applied in patients with differentiated thyroid cancer (DTC) to improve the disease outcome. Over the last decades several authors have closely monitored the potential harm suffered by the skeletal system. Several studies and meta-analyses have shown that chronic TSH suppressive therapy is safe in premenopausal women and men. Conversely, in postmenopausal women TSH suppressive therapy is associated with a decrease of bone mineral density, deterioration of bone architecture (quantitative CT, QCT; trabecular bone score, TBS), and, possibly, an increased risk of fractures. The TSH receptor is expressed in bone cells and the results of experimental studies in TSH receptor knockout mice and humans on whether low TSH levels, as opposed to solely high thyroid hormone levels, might contribute to bone loss in endogenous or exogenous thyrotoxicosis remain controversial. Recent guidelines on the use of TSH suppressive therapy in patients with DTC give value not only to its benefit on the outcome of the disease, but also to the risks associated with exogenous thyrotoxicosis, namely menopause, osteopenia or osteoporosis, age >60 years, and history of atrial fibrillation. Bone health (BMD and/or preferably TBS) should be evaluated in postmenopausal women under chronic TSH suppressive therapy or in those patients planning to be treated for several years. Antiresorptive therapy could also be considered in selected cases (increased risk of fracture or significant decline of BMD/TBS during therapy) to prevent bone loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.